Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib

Yuh Min Chen, Wen Chien Fan, Pei Chun Tseng, Chun Ming Tsai, Teh Ying Chou, Chieh Hung Wu, Kun Ta Chou, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    Tumor epidermal growth factor receptor (EGFR) mutation analysis is significant for making treatment decisions for metastatic pulmonary adenocarcinoma. However, less than half of patients have adequate tumor samples for mutation analysis. Patients with adenocarcinoma of the lungs who were due to receive erlotinib treatment were included in the present study. Tumor EGFR mutation status was analyzed using DNA sequencing. Plasma specimens from the patients were collected prior to erlotinib treatment. The plasma-free DNA EGFR mutation status was analyzed using the PCR clamp method. A total of 54 consecutive patients were included in the study. The plasma-free DNA EGFR mutation status of the 54patients was analyzed. Only 30patients had adequate tumor samples for EGFR analysis, including 15 with activating mutations (exon 19 deletions or L858R). EGFR-activating mutations were detected in the plasma-free DNA in 25 of 54patients. The response rate was 86.7 and 33.3% in patients with and without tumor activating mutations, respectively (p=0.002). The response rate was 68 and 31% based on the patients' plasma-free DNA EGFR mutation status, respectively (p=0.013). No significant difference in progression-free survival(PFS) was observed between patients with and without EGFR-activating mutations, according to data from tumor tissue or plasma-free DNA analysis, although the median PFS time was longer for those patients with EGFR-activating mutations in plasma samples. Plasma EGFR mutation analysis is useful for adenocarcinoma patients who have no or inadequate tumor samples available for EGFR examination. Patients with plasma EGFR-activating mutations had an improved response rate and a statistically insignificant longer PFS.

    Original languageEnglish
    Pages (from-to)713-717
    Number of pages5
    JournalOncology Letters
    Volume3
    Issue number3
    DOIs
    Publication statusPublished - Mar 2012

    Fingerprint

    Epidermal Growth Factor Receptor
    Mutation
    Neoplasms
    DNA
    Disease-Free Survival
    Adenocarcinoma of lung
    Erlotinib Hydrochloride
    DNA Sequence Analysis
    Exons
    Decision Making
    Adenocarcinoma
    Therapeutics

    Keywords

    • Adenocarcinoma
    • Epidermal growth factor receptor
    • Erlotinib
    • Targeted therapy

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. / Chen, Yuh Min; Fan, Wen Chien; Tseng, Pei Chun; Tsai, Chun Ming; Chou, Teh Ying; Wu, Chieh Hung; Chou, Kun Ta; Lee, Yu Chin; Perng, Reury Perng; Whang-Peng, Jacqueline.

    In: Oncology Letters, Vol. 3, No. 3, 03.2012, p. 713-717.

    Research output: Contribution to journalArticle

    Chen, Yuh Min ; Fan, Wen Chien ; Tseng, Pei Chun ; Tsai, Chun Ming ; Chou, Teh Ying ; Wu, Chieh Hung ; Chou, Kun Ta ; Lee, Yu Chin ; Perng, Reury Perng ; Whang-Peng, Jacqueline. / Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. In: Oncology Letters. 2012 ; Vol. 3, No. 3. pp. 713-717.
    @article{b01f03a4517f41ec8d7240bd4cd26db3,
    title = "Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib",
    abstract = "Tumor epidermal growth factor receptor (EGFR) mutation analysis is significant for making treatment decisions for metastatic pulmonary adenocarcinoma. However, less than half of patients have adequate tumor samples for mutation analysis. Patients with adenocarcinoma of the lungs who were due to receive erlotinib treatment were included in the present study. Tumor EGFR mutation status was analyzed using DNA sequencing. Plasma specimens from the patients were collected prior to erlotinib treatment. The plasma-free DNA EGFR mutation status was analyzed using the PCR clamp method. A total of 54 consecutive patients were included in the study. The plasma-free DNA EGFR mutation status of the 54patients was analyzed. Only 30patients had adequate tumor samples for EGFR analysis, including 15 with activating mutations (exon 19 deletions or L858R). EGFR-activating mutations were detected in the plasma-free DNA in 25 of 54patients. The response rate was 86.7 and 33.3{\%} in patients with and without tumor activating mutations, respectively (p=0.002). The response rate was 68 and 31{\%} based on the patients' plasma-free DNA EGFR mutation status, respectively (p=0.013). No significant difference in progression-free survival(PFS) was observed between patients with and without EGFR-activating mutations, according to data from tumor tissue or plasma-free DNA analysis, although the median PFS time was longer for those patients with EGFR-activating mutations in plasma samples. Plasma EGFR mutation analysis is useful for adenocarcinoma patients who have no or inadequate tumor samples available for EGFR examination. Patients with plasma EGFR-activating mutations had an improved response rate and a statistically insignificant longer PFS.",
    keywords = "Adenocarcinoma, Epidermal growth factor receptor, Erlotinib, Targeted therapy",
    author = "Chen, {Yuh Min} and Fan, {Wen Chien} and Tseng, {Pei Chun} and Tsai, {Chun Ming} and Chou, {Teh Ying} and Wu, {Chieh Hung} and Chou, {Kun Ta} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline Whang-Peng",
    year = "2012",
    month = "3",
    doi = "10.3892/ol.2011.534",
    language = "English",
    volume = "3",
    pages = "713--717",
    journal = "Oncology Letters",
    issn = "1792-1074",
    publisher = "Spandidos Publications",
    number = "3",

    }

    TY - JOUR

    T1 - Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib

    AU - Chen, Yuh Min

    AU - Fan, Wen Chien

    AU - Tseng, Pei Chun

    AU - Tsai, Chun Ming

    AU - Chou, Teh Ying

    AU - Wu, Chieh Hung

    AU - Chou, Kun Ta

    AU - Lee, Yu Chin

    AU - Perng, Reury Perng

    AU - Whang-Peng, Jacqueline

    PY - 2012/3

    Y1 - 2012/3

    N2 - Tumor epidermal growth factor receptor (EGFR) mutation analysis is significant for making treatment decisions for metastatic pulmonary adenocarcinoma. However, less than half of patients have adequate tumor samples for mutation analysis. Patients with adenocarcinoma of the lungs who were due to receive erlotinib treatment were included in the present study. Tumor EGFR mutation status was analyzed using DNA sequencing. Plasma specimens from the patients were collected prior to erlotinib treatment. The plasma-free DNA EGFR mutation status was analyzed using the PCR clamp method. A total of 54 consecutive patients were included in the study. The plasma-free DNA EGFR mutation status of the 54patients was analyzed. Only 30patients had adequate tumor samples for EGFR analysis, including 15 with activating mutations (exon 19 deletions or L858R). EGFR-activating mutations were detected in the plasma-free DNA in 25 of 54patients. The response rate was 86.7 and 33.3% in patients with and without tumor activating mutations, respectively (p=0.002). The response rate was 68 and 31% based on the patients' plasma-free DNA EGFR mutation status, respectively (p=0.013). No significant difference in progression-free survival(PFS) was observed between patients with and without EGFR-activating mutations, according to data from tumor tissue or plasma-free DNA analysis, although the median PFS time was longer for those patients with EGFR-activating mutations in plasma samples. Plasma EGFR mutation analysis is useful for adenocarcinoma patients who have no or inadequate tumor samples available for EGFR examination. Patients with plasma EGFR-activating mutations had an improved response rate and a statistically insignificant longer PFS.

    AB - Tumor epidermal growth factor receptor (EGFR) mutation analysis is significant for making treatment decisions for metastatic pulmonary adenocarcinoma. However, less than half of patients have adequate tumor samples for mutation analysis. Patients with adenocarcinoma of the lungs who were due to receive erlotinib treatment were included in the present study. Tumor EGFR mutation status was analyzed using DNA sequencing. Plasma specimens from the patients were collected prior to erlotinib treatment. The plasma-free DNA EGFR mutation status was analyzed using the PCR clamp method. A total of 54 consecutive patients were included in the study. The plasma-free DNA EGFR mutation status of the 54patients was analyzed. Only 30patients had adequate tumor samples for EGFR analysis, including 15 with activating mutations (exon 19 deletions or L858R). EGFR-activating mutations were detected in the plasma-free DNA in 25 of 54patients. The response rate was 86.7 and 33.3% in patients with and without tumor activating mutations, respectively (p=0.002). The response rate was 68 and 31% based on the patients' plasma-free DNA EGFR mutation status, respectively (p=0.013). No significant difference in progression-free survival(PFS) was observed between patients with and without EGFR-activating mutations, according to data from tumor tissue or plasma-free DNA analysis, although the median PFS time was longer for those patients with EGFR-activating mutations in plasma samples. Plasma EGFR mutation analysis is useful for adenocarcinoma patients who have no or inadequate tumor samples available for EGFR examination. Patients with plasma EGFR-activating mutations had an improved response rate and a statistically insignificant longer PFS.

    KW - Adenocarcinoma

    KW - Epidermal growth factor receptor

    KW - Erlotinib

    KW - Targeted therapy

    UR - http://www.scopus.com/inward/record.url?scp=84862939146&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84862939146&partnerID=8YFLogxK

    U2 - 10.3892/ol.2011.534

    DO - 10.3892/ol.2011.534

    M3 - Article

    VL - 3

    SP - 713

    EP - 717

    JO - Oncology Letters

    JF - Oncology Letters

    SN - 1792-1074

    IS - 3

    ER -